Key Findings

Step therapy restrictions increased significantly in both the Medicare and commercial plan types. The increases were rapid for Medicare, suggesting that Medicare plans responded to the availability of zolpidem by placing step therapy restrictions, instead of immediate tier changes. In the Medicare market, Ambien CR, and Rozerem experienced rapid increases in ST restrictions during the analysis period. In the commercial market, Ambien CR, Lunesta, Rozerem and Sonata all experienced significant increases in ST restrictions.

Printable version

Collateral Formulary Access Impact in the Sleep Disorder Class due to Patent Loss for Ambien (PDF 314KB)

Archives

December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market

October 2007: Formulary Position Differences between Commercial and Medicare Plans

September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace